Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. ("Shengyao Guangyan"), a wholly‑owned subsidiary of Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE: 002370), signed a Letter of Intent (LOI) for Innovative Drug Technology Transaction…

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo
CompanyDrug

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn's Disease – 35.8% Achieved Endoscopic Remission
CompanyDrug

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn’s Disease – 35.8% Achieved Endoscopic Remission

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children
CompanyDrug

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn's Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success
CompanyDrug

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn’s Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success

- Advertisement -
Ad image
CompanyDrug

Nhwa Pharmaceutical Wins NMPA IND Approval for Two Category 1 Chemical Drugs – NH130 for Schizophrenia & Alzheimer’s Psychosis, NH302 for Acute Pain

CompanyDrug

CSPC Pharmaceutical’s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First‑Line Advanced Breast Cancer – HER2 Bispecific Combo Advances in China

CompanyDeals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

CompanyDrug

Betta Pharmaceuticals Partner EyePoint Reports EYP‑1901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD – DURAVYU Fails Non‑Inferiority vs. Aflibercept

CompanyDeals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
CompanyDrug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
CompanyDeals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

CompanyDrug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

CompanyDrug

CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform
CompanyDeals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

CompanyDeals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
CompanyDrug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Show More